China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

InnoCare Pharma And Eli Lilly And Company Announce Strategic Research Collaboration And License Agreement To Develop New Medicines

InnoCare Pharma announced that the Company has entered into a strategic research collaboration and license agreement with Eli Lilly and Company to develop new medicines. InnoCare will leverage its...

InnoCare inks licensing deal with Eli Lilly worth up to $3.35B (LLY:NYSE)

InnoCare Pharma (INCPF) partners with Eli Lilly (LLY) to develop new medicines; up to $100M upfront, $3.25B milestones + royalties.

InnoCare Announces Strategic Research Collaboration and License Agreement with Lilly to Develop New Medicines

BEIJING, Sept. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune...

China's InnoCare, Eli Lilly sign collaboration deal worth up to $3.35 billion

Chinese drugmaker InnoCare Pharma said ​on Thursday it had entered ‌into a research collaboration and licensing agreement with Eli Lilly worth up to ​about $3.35 billion.

InnoCare Pharma Strikes Multibillion-Dollar Drug Discovery Pact With Eli Lilly

InnoCare Pharma Ltd. ( ($HK:9969) ) has provided an announcement. InnoCare Pharma has entered into a strategic research collaboration and license agreement with glo...